Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- A five-year pharmacovigilance study analyzing nearly 4 million patients across 60 countries confirms the excellent safety profile of NTC's fixed-dose combination eye drops containing dexamethasone and levofloxacin for post-cataract surgery care. - The study identified only 53 adverse drug reactions in 25 patients between 2020 and 2024, with 74% being non-serious and more than half deemed unlikely related to the product. - No cases of endophthalmitis, a severe post-surgical eye infection, were reported, supporting the seven-day treatment regimen that improves patient adherence while minimizing antibiotic resistance risks. - The findings represent the first international pharmacovigilance study specifically focused on fixed-dose eye drops combining an antibiotic and anti-inflammatory steroid for cataract surgery patients.
- NTC014, a combination of quinolone antibiotic and NSAID eye drops, shows promise in treating bacterial conjunctivitis in adults. - The Phase II MIRAKLE study demonstrated NTC014's non-inferiority to antibiotic-only treatment in microbiological eradication. - NTC014 exhibited efficacy against pathogens with intermediate or resistant to the tested quinolone antibiotic. - NTC aims to finalize commercial partnerships for NTC014 in most countries by the end of 2025, with potential for surgical applications.
